The White House is conducting private meetings with pharmaceutical companies to build support for drug pricing legislation, according to STAT News. The outreach represents part of the Biden administration's election year focus on making medications more affordable for Americans.
The administration's approach of directly engaging with pharmaceutical companies suggests a strategy to avoid the industry opposition that has historically derailed drug pricing reforms. By seeking to build consensus before formal legislative action, the White House appears to be taking a more collaborative approach than previous attempts at drug pricing reform.